New research demonstrates how specially engineered bacteria taken orally can operate as a delivery system for vaccines and antiviral therapies.

The FDA also requested Novavax conduct a phase 4 study in patients aged 50 to 64 years without high-risk conditions for severe COVID-19.

Good evening and welcome to the Dyadic International First Quarter 2025 Financial Results Conference Call. Currently, all participants are in a listen-only mode. Following management's prepared ...

Dyadic International, Inc. ("Dyadic”, "we”, "us”, "our”, or the "Company”) (NASDAQ: DYAI), a biotechnology company specializing in the development of functional recombinant solutions and proprietary ...

The world market for recombinant proteins remains strong, with North America and Europe dominating research and development as a result of their strong biopharmaceutical industries. The Asia-Pacific ...

The Trump administration is investing $500M in a project to develop "universal" vaccines that protect against multiple virus strains at once, The Wall Street Journal reported, citing emails it ...

Professor Emeritus Herb Boyer's discovery of recombinant DNA changed medicine, ushering in a new era in biological treatments ...

Few neighborhoods in Cambridge have seen their fortunes change as dramatically as Kendall Square. Kendall was once known for churning out soap and vulcanized rubber, then manufacturing electronics ...

The synthetic MVA system efficiently generates recombinant vaccines with robust immune responses ... five plasmids covering the full viral genome from chemically synthesized DNA, which is convenient ...

It folds the genetic material DNA into desired shapes to isolate only the cells affected by the hard-to-treat pancreatic cancer and to create cancer vaccines that enhance the body's immunity.